Citius Pharmaceuticals Inc vs Kraft Heinz Co — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while Kraft Heinz Co trades at $24.36 (market cap $29.23B). The key difference: Kraft Heinz Co is far larger — about 1460.8× Citius Pharmaceuticals Inc's market cap, and Kraft Heinz Co pays a 6.49% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | KHC | |
|---|---|---|
Market Cap | $20.01M | $29.23B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $28.06 |
52-Week Low | $0.48 | $21.21 |
Enterprise Value | $16.23M | $45.55B |
Dividend Yield | — | 6.49% |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Kraft Heinz (KHC) trades at $24.36, down 2.29% today, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates, but net income margin is negative at -13.64%. The company maintains a $0.40 quarterly dividend, while analyst consensus is mostly Hold. Cash flow from operations improved to $4.46B in 2025, though revenue declined to $24.94B.
Outlook remains cautious due to profit declines and competitive pressures, offset by a low P/E of 13.04 and strategic investments. Key risks include earnings sustainability and high debt. The stock presents value potential but requires monitoring of turnaround execution under CEO Cahillane's strategy.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →